Business
CHOSA: Significant clinical progress and strengthened financial position with new capital raised in Q3 2025
CHOSA: Significant clinical progress and strengthened financial position with new capital raised in Q3 2025
About this update from Chosa Oncology Ab
Q3 2025 saw major clinical and strategic advances, including validation of Platin-DRP® for both cisplatin and carboplatin, new breast cancer data, and a win at a major entrepreneurship contest in China. Financials showed a net loss, strong equity ratio, and successful capital raises.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.